Dr. Martens PLC Director/PDMR Shareholding

RNS Number : 9554L

Dr. Martens PLC

12 November 2024

 

Dr. Martens plc (the 'Company')

Director/PDMR Shareholding

Notification of Transactions by Directors/Persons Discharging Managerial Responsibility

The Company announces that it was notified on 12 November 2024 of the following transactions in the Company's Ordinary 1p shares undertaken by directors / persons discharging managerial responsibility ('PDMRs') under the Company's Share Incentive Plan ('SIP').

The SIP is an HMRC approved, all-employee scheme under which participating employees are able to purchase shares in the Company from monthly salary ('Partnership Shares') and receive allocations of free 'Matching Shares', awarded at a rate of one Matching Share for every one Partnership Share purchased by a participating employee, from the Company.

 

On 11 November 2024, the following directors / PDMRs acquired Partnership Shares as a result of their participation in the SIP at a price of 57.15p pence per share and were granted an allocation of Matching Shares (for no consideration) in the quantity set out in the table below:

 

Director / PDMR	Number of Partnership Shares purchased	Number of Matching Shares awarded
Kenny Wilson	262	262
Giles Wilson	263	263

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

 

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Kenneth Wilson
2	Reason for the notification
a)	Position/status	PDMR (Chief Executive Officer)
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Dr. Martens plc
b)	LEI	213800QPT8YM6NQZPH28
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of GBP 0.01 ISIN: GB00BL6NGV24
b)	Nature of the transaction	1.     Purchase of Partnership Shares under the SIP 2.     Award of Matching Shares under the SIP
c)	Price(s) and volume(s)	Price(s) Volume(s) 1. 57.15p 262 2. Nil 262
d)	Aggregated information   - Aggregated volume - Price     - Aggregated volume - Price	1. Partnership shares 262 57.15p     2. Matching shares 262 Nil
e)	Date of the transaction	11 November 2024
f)	Place of the transaction	1.     London Stock Exchange (XLON) 2.     Outside of a trading venue

 

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Giles Wilson
2	Reason for the notification
a)	Position/status	PDMR (Chief Financial Officer)
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Dr. Martens plc
b)	LEI	213800QPT8YM6NQZPH28
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of GBP 0.01 ISIN: GB00BL6NGV24
b)	Nature of the transaction	1.     Purchase of Partnership Shares under the SIP 2.     Award of Matching Shares under the SIP
c)	Price(s) and volume(s)	Price(s) Volume(s) 1. 57.15p 263 2. Nil 263
d)	Aggregated information   - Aggregated volume - Price     - Aggregated volume - Price	1. Partnership shares 263 57.15p      2. Matching shares 263 Nil
e)	Date of the transaction	11 November 2024
f)	Place of the transaction	1.     London Stock Exchange (XLON) 2.     Outside of a trading venue

 

 

For further information please contact:

 

 

Rebecca Flaherty

Company Secretarial Assistant

[phone]           

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

DSHUUVVRSSUAAAA